EGFR and non-small cell lung carcinoma: MET amplification has been detected in 1% to 5.8% of treatment-naïve NSCLC patients [9,10,11,12,13,14,15,16,17] and in 5% to 26% of patients with EGFR-mutant NSCLC who develop resistant to EGFR inhibitors [13,14,15,16,18,19,20].